China is mulling over establishing a Brain-Computer Interface (BCI) standardization technical committee under its Ministry of Industry and Information Technology (MIIT), aiming to guide enterprises to enhance industrial standards and boost domestic innovation. The proposed committee, revealed by the MIIT on Monday, will work on composing a BCI standards roadmap for the entire industry development as well as the standards for the research and development of the key technologies involved, according to the MIIT. China has taken strides in developing the BCI industry over the years, not only providing abundant policy support but also generous financial investment, Li Wenyu, secretary of the Brain-Computer Interface Industrial Alliance, told the Global Times. From last year to 2024, both the central and local governments have successively issued relevant policies to support industrial development. The MIIT in 2023 rolled out a plan selecting and promoting a group of units with strong innovation capabilities to break through landmark technological products and accelerate the application of new technologies and products. The Beijing local government also released an action plan to accelerate the industry in the capital (2024-2030) this year. In 2023, there were no fewer than 20 publicly disclosed financing events for BCI companies in China, with a total disclosed amount exceeding 150 million yuan ($20.6 million), Li said. “The strong support from the government has injected momentum into industrial innovation.” The fact that China's BCI industry started later than Western countries such as the US is a reality, leading to the gap in China regarding technological breakthroughs, industrial synergy, and talent development, according to Li. To further close gaps and solve bottlenecks in BCI industrial development, Li suggested that the industry explore various technological approaches to suit different application scenarios and encourage more medical facilities powered by BCI to initiate clinical trials by optimizing the development of BCI-related ethics. Additionally, he highlighted that standard development is one of the aspects to enhance the overall level and competitiveness of the industry chain, which could, in turn, empower domestic BCI innovation. While China's BCI technology generally lags behind leading countries like the US in terms of system integration and clinical application, this has not hindered the release of Neucyber, which stands as China's first "high-performance invasive BCI." Neucyber, an invasive implanted BCI technology, was independently developed by Chinese scientists from the Chinese Institute for Brain Research in Beijing. Li Yuan, Business Development Director of Beijing Xinzhida Neurotechnology, the company that co-developed this BCI system, told the Global Times that the breakthrough of Neucyber could not have been achieved without the efforts of the institute gathering superior resources from various teams in Beijing. A group of mature talents were gathered within the institute, from specific fields involving electrodes, chips, algorithms, software, and materials, Li Yuan said. Shrugging off the outside world's focus on China’s competition with the US in this regard, Li Yuan said her team doesn’t want to be imaginative and talk too much, but strives to produce a set of products step by step that can be useful in actual applications. In addition, Li Wenyu also attributed the emergence of Neucyber to the independent research atmosphere and the well-established talent nurturing mechanism in the Chinese Institute for Brain Research. He said that to advance China’s BCI industry, it is necessary not only to cultivate domestic talents but also to introduce foreign talents to enhance China's research and innovation capabilities. The proposed plan for establishing the BCI standardization technical committee under the MIIT will solicit public opinions until July 30, 2024.

A look at the day ahead in U.S. and global markets from Mike Dolan After an intense month focused on election risk around the world, markets quickly switched back to the more prosaic matter of the cost of money - and whether disinflation is resuming to the extent it allows borrowing costs to finally fall. Thursday's U.S. consumer price update for June is the key moment of the week for many investors - with the headline rate expected to have fallen two tenths of a percentage point to 3.1% but with 'core' rates still stuck at 3.4%. With Federal Reserve chair Jerome Powell starting his two-pronged semi-annual congressional testimony later on Tuesday, the consensus CPI forecast probably reflects what the central bank thinks of the situation right now - encouraging but not there yet. But as the U.S. unemployment rate is now back above 4.0% for the first time since late 2021, markets may look for a more nuanced approach from the Fed chair that sees it increasingly wary of a sudden weakening of the labor market as real time quarterly GDP estimates ebb again to about 1.5%. There were some other reasons for Fed optimism in the lead up to the testimony. The path U.S. inflation is expected to follow over coming years generally softened in June, amid retreating projections of price increases for a wide array of consumer goods and services, a New York Fed survey showed on Monday. Inflation a year from now was seen at 3% as of June - down from the expected rise of 3.2% in May - and five-year expectations fell to 2.8% from 3%. Crude oil prices are better behaved this week, too, falling more than 3% from the 10-week highs hit late last week and halving the annual oil price gain to 10%. The losses on Tuesday came after a hurricane that hit a key U.S. oil-producing hub in Texas caused less damage than many in markets had expected - easing concerns over supply disruption. Before Powell starts speaking later, there will also be an update on U.S. small business confidence for last month.

On July 8, local time, former British Prime Minister Sunak announced the appointment of the Conservative Party Shadow Cabinet, which is the first shadow cabinet of the Conservative Party in 14 years. Several former British cabinet members during Sunak's tenure as prime minister were appointed to the Conservative Party Shadow Cabinet, including James Cleverly as Shadow Home Secretary and Jeremy Hunt as Shadow Chancellor of the Exchequer. But former Foreign Secretary Cameron was not appointed as Shadow Foreign Secretary. In addition, the new leader of the Conservative Party will be elected as early as this week. On July 4, the UK held a parliamentary election. The counting results showed that the British Labour Party won more than half of the seats and won an overwhelming victory; the Conservative Party suffered a disastrous defeat, ending its 14-year continuous rule.

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.

The tetraprism lens with 5x optical zoom currently exclusive to the iPhone 15 Pro Max could be headed to both the iPhone 16 Pro and iPhone 16 Pro Max, narrowing the gap between Apple's premium flagships. That's according to a new report from analyst Ming-Chi Kuo, who cites a recent earnings call with Apple lens supplier Largan. In the call, a spokesperson from Largan said "some flagship specifications will be extended to other models" in the second half of 2024, presumably in reference to the upcoming iPhone Pro models. "Apple is Largan’s largest customer, and Largan is also Apple’s largest lens supplier," Kuo said. "Therefore, the quote likely refers to the fact that the new iPhone 16 Pro and Pro Max will have a tetraprism camera in 2H24 (while only the iPhone 15 Pro Max had this camera in 2H23).” The report goes on to say that the tetraprism camera for the iPhone 16 Pro series won't be all that different from the one in the iPhone 15 Pro Max. While the lack of an upgrade is disappointing, it's not necessarily a bad thing as these kinds of lenses are already top-of-the-line. They represent a major increase over prior models’ zoom capabilities, and they're capable of offering more depth while still fitting into super-slim smartphones. That being said, Apple does appear to be revamping the main camera and ultra-wide camera on the iPhone 16 Pro Max. Evidence continues to mount that both iPhone 16 Pro models will share the same 5x optical zoom camera. Earlier this week, DigitTimes in Asia (via 9to5Mac) reported that Apple is set to ramp up orders for tetraprism lenses as it expands their use in its upcoming iPhone series. Industry sources told the outlet that Largan and Genius Electronic Optical were tapped as the primary suppliers. Apple would be wise to streamline its Pro-level iPhones with the same camera setup; then all customers have to consider with their choice of a new iPhone is the size and price. Of course, this should all be taken with a grain of sand for now until we hear more from Apple. It's still a while yet before Apple's usual September time window for iPhone launches. In the meantime, be sure to check out all the rumors so far in our iPhone 16, iPhone 16 Pro and iPhone 16 Pro Max hubs.